US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

611.92

-13.4269-2.15%

Number of Gainers:1

Number of Losers:3

Number of Flat:- -

PE:- -

High:625.56

Open:625.56

Low:604.19

Close:625.35

Volume:15.61M

Turnover:267.53M

Market Cap:19.03B

Float Cap:14.56B

Loading ...

Recursion Q2 Net Loss Narrows to $131.01 Million; Revenue Drops to $7.67 Million

Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate

Benzinga Earnings

Recursion Pharmaceuticals Q2 Net Income USD -131.005 Million

THOMSON REUTERS

Recursion Pharmaceuticals Inc: Reduced 2026 Cash Operating Expense Guidance to <$375 Mln

THOMSON REUTERS

Press Release: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Clear Street Remains a Buy on Beam Therapeutics (BEAM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

MT Newswires Live

Tempus AI announces study results of PRISM2

Beam Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Recursion to Present at Bank of America SMID Cap Executive Insights Event

Recursion to Participate in Upcoming Investor Conferences

Beam Therapeutics Q2 Operating Expenses USD 127.043 Million

THOMSON REUTERS

Beam Therapeutics Q2 License and Collaboration Revenue USD 490 Thousand

THOMSON REUTERS

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of Beam-302 Trial in Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Tempus AI Inc : Btig Cuts Target Price to $70 from $80

THOMSON REUTERS

Crispr Therapeutics AG Reports Results for the Quarter Ended June 30 - Earnings Summary

Crispr Therapeutics Q2 FY26 Net Loss Narrows to $91.2 Million; Casgevy Revenue Rises 151% Year over Year to $76 Million

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Rocket Pharmaceuticals (RCKT)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4611/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":611.922,"timestamp":1786737599999,"preClose":625.3489,"halted":0,"volume":15605073,"delay":0,"changeRate":-0.021471,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-13.42688,"latestTime":"08-14 16:00:00 EDT","open":625.56323,"high":625.56323,"low":604.1918,"amount":267531092.097252,"amplitude":0.034175,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.657559,"peRate":-14.828987,"turnoverRate":0.019463,"increases":1,"decrements":3,"flats":0,"marketCap":19032084608,"floatMarketCap":14555207936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":625.56323,"amplitude":0.034175,"preClose":625.3489,"low":604.1918,"pbRate":"4.657559","latestPrice":611.922,"volume":15605073,"delay":0,"open":625.56323,"prevYearClose":658.3995,"prevWeekClose":614.7909,"prevMonthClose":543.3925,"prevQuarterClose":681.0329,"fiveDayClose":614.7909,"twentyDayClose":590.2628,"sixtyDayClose":550.7017,"secType":"PLATE","market":"US","turnoverRate":0.019463,"peRate":-14.828987,"marketCap":19032084608,"floatMarketCap":14555207936,"timestamp":1786737599999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":1,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657543594","title":"Recursion Q2 Net Loss Narrows to $131.01 Million; Revenue Drops to $7.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543594","media":"Reuters","labels":["corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543594?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:31","pubTimestamp":1785925903,"startTime":"0","endTime":"0","summary":"Recursion Q2 net loss narrows to $131.01 million; revenue drops to $7.67 millionRecursion posted Q2 net loss of USD 131 million, narrowing from USD 171.9 million a year earlier; revenue fell 59.93% to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9S66Q1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4548","BK4609","BK4611","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543844","title":"Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543844","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543844?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:31","pubTimestamp":1785925860,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60941020/recursion-pharmaceuticals-q2-eps-0-25-misses-0-22-estimate-sales-7-670m-miss-11-947m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4611","BK4139","BK4548","RXRX","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657754875","title":"Recursion Pharmaceuticals Q2 Net Income USD -131.005 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657754875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657754875?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXG5D2DP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4139","RXRX","BK4609","BK4539","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548761","title":"Recursion Pharmaceuticals Inc: Reduced 2026 Cash Operating Expense Guidance to <$375 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548761?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXG5D2DP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4539","RXRX","BK4609","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543891","title":"Press Release: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543891?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":"-- Genentech advanced the collaboration's first neuroscience target into a. joint early discovery program, providing early evidence that Recursion's. platform can generate novel, biologically validated targets for drug. -- REC-4881 : Additional Phase 2 data in Familial. Adenomatous Polyposis  to be presented at the Presidential Plenary. session at leading hereditary GI annual meeting in November 2026. -- REC-7735 : IND cleared, Phase 1/2 trial. start in 2H26; a >100× mutant-selective PI3K<ALPHA> H1047R inhibitor. designed to improve therapeutic index by enabling deep suppression of the. most common activating PI3K<ALPHA> mutation while sparing wild-type. -- Reduced 2026 cash operating expense guidance to <$375 million (from <$390","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4611","BK4539","BK4139","BK4548","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657517142","title":"Clear Street Remains a Buy on Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657517142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657517142?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:35","pubTimestamp":1785922545,"startTime":"0","endTime":"0","summary":"In a report released today, William Maughan from Clear Street maintained a Buy rating on Beam Therapeutics, with a price target of $37.00. Accordin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/clear-street-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/clear-street-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4139","BK4588","BEAM","BK4556","BK4611","BK4585","BK4535","LU1861559042.SGD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657456873","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657456873","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657456873?lang=en_us&edition=fundamental","pubTime":"2026-08-05 01:20","pubTimestamp":1785864028,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), Rhythm Pharmaceuticals (RY...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-275?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-275?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","BK4505","BK4588","RYTM","BK4556","BK4139","LU1861558580.USD","BK4611","LU1861559042.SGD","BK4535","BEAM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555065","title":"Crispr Therapeutics Posts \"Quiet\" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555065","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555065?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:49","pubTimestamp":1785858594,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics  reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.RBC maintained its sector perform rating on the stock ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1861558580.USD","LU1861559042.SGD","LENZ","BK4585","BK4539","BK4007","BK4139","CRSP","BK4588","BK4611","BK4556","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556427","title":"Tempus AI announces study results of PRISM2","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556427?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:36","pubTimestamp":1785846992,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-study-results-of-prism2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-study-results-of-prism2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TEMT","HEAL","BK4611","LU1861558580.USD","LU1861559042.SGD","BK4613","TEM","BK4121","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656206555","title":"Beam Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656206555","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656206555?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:17","pubTimestamp":1785845839,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryBeam Therapeutics IncBEAM.OQreported a quarterly adjusted loss of $1.18 per share for the quarter ended June 30, l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU1861559042.SGD","BK4139","BK4535","BK4588","BK4585","BK4611","BK4556","BEAM","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656649555","title":"Recursion to Present at Bank of America SMID Cap Executive Insights Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2656649555","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656649555?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:05","pubTimestamp":1785845125,"startTime":"0","endTime":"0","summary":"Recursion to present at Bank of America SMID Cap Executive Insights eventRecursion will attend the Bank of America 2026 SMID Cap Executive Insights Event on Aug. 11, 2026.It will also participate in t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLc02Phc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RXRX","BK4139","BK4611","BK4609","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656497556","title":"Recursion to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2656497556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656497556?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844800,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals. media@recursion.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338226/0/en/Recursion-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4548","BK4609","BK4611","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530329","title":"Beam Therapeutics Q2 Operating Expenses USD 127.043 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530329?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLX6JSPDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861558580.USD","BK4505","BEAM","BK4535","BK4585","BK4611","BK4588","BK4556","LU1861559042.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656153037","title":"Beam Therapeutics Q2 License and Collaboration Revenue USD 490 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2656153037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656153037?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLX6JSPDZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4611","BK4588","BK4585","BK4535","LU1861558580.USD","BK4556","BEAM","BK4139","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530813","title":"Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of Beam-302 Trial in Alpha-1 Antitrypsin Deficiency (Aatd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530813?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA6FCZCJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4505","LU1861558580.USD","BK4139","BK4611","BEAM","BK4556","BK4535","BK4588","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558343","title":"Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558343","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558343?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":"Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in P","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338130/0/en/Beam-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Announces-First-Patient-Dosed-in-Global-Pivotal-Cohort-of-BEAM-302-Trial-in-Alpha-1-Antitrypsin-Deficiency-AATD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4611","BK4535","BEAM","BK4139","IDNA","LU1861558580.USD","IND","BK4588","SCD","LU1861559042.SGD","BK4585","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656320584","title":"Tempus AI Inc : Btig Cuts Target Price to $70 from $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2656320584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656320584?lang=en_us&edition=fundamental","pubTime":"2026-08-04 12:47","pubTimestamp":1785818835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4410CE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARKG","BK4121","BK4611","HEAL","LU1861559042.SGD","TEMT","BK4613","TEM","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656830710","title":"Crispr Therapeutics AG Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656830710","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656830710?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:38","pubTimestamp":1785793117,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG reports results for the quarter ended June 30 - Earnings SummaryCRISPR Therapeutics AGCRSP.OQreported a quarterly adjusted loss of 94 cents per share for the quarter ended June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4556","BK4139","LU1861558580.USD","ARKG","BK4611","LU1861559042.SGD","BK4585","CRSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656230453","title":"Crispr Therapeutics Q2 FY26 Net Loss Narrows to $91.2 Million; Casgevy Revenue Rises 151% Year over Year to $76 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656230453","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656230453?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:22","pubTimestamp":1785788541,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics Q2 FY26 net loss narrows to $91.2 million; CASGEVY revenue rises 151% year over year to $76 millionCRISPR Therapeutics posted a Q2 net loss of $91.2 million, narrowing from $208.5 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLcnb8h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","CRSP","BK4588","BK4611","BK4139","LU1861559042.SGD","IE00BN0W2T93.GBP","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","BK4112","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","LU1861558580.USD","LU2095319765.USD","ARKG","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","BCDF","BK4556","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656305691","title":"Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Rocket Pharmaceuticals (RCKT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656305691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656305691?lang=en_us&edition=fundamental","pubTime":"2026-08-04 01:40","pubTimestamp":1785778806,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tempus AI, Inc. Class A (TEM) and Rocket Pharmaceuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tempus-ai-inc-class-a-tem-and-rocket-pharmaceuticals-rckt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tempus-ai-inc-class-a-tem-and-rocket-pharmaceuticals-rckt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKG","BK4613","TEM","LU1861558580.USD","RCKT","HEAL","BK4611","BK4121","TEMT","LU1861559042.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}]}}